Search

Your search keyword '"A. Cruz-Bermudez"' showing total 137 results

Search Constraints

Start Over You searched for: Author "A. Cruz-Bermudez" Remove constraint Author: "A. Cruz-Bermudez"
137 results on '"A. Cruz-Bermudez"'

Search Results

1. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

3. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium

4. Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study

5. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

6. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

7. Making EHRs Trustable: A Quality Analysis of EHR-Derived Datasets for COVID-19 Research

8. Building an i2b2-Based Population Repository for COVID-19 Research

10. Obtaining EHR-derived datasets for COVID-19 research within a short time: a flexible methodology based on Detailed Clinical Models

11. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

13. Validation of extracorporeal membrane oxygenation mortality prediction and severity of illness scores in an international COVID-19 cohort

14. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

15. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

18. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

19. Evaluation of the Perception of a University Group of Teachers about Education as a Social Phenomenon in Colombia

20. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

21. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

22. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

23. P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival

25. OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC

26. Profiling Lung Cancer Patients Using Electronic Health Records

27. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

28. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

29. Building an i2b2-Based Population Repository for COVID-19 Research

30. Building an i2b2-Based Population Repository for COVID-19 Research

31. Making EHRs Trustable: A Quality Analysis of EHR-Derived Datasets for COVID-19 Research

32. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

33. Impact of first year renal replacement therapy on the hospital admissions of a regional public health system

34. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial

35. Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

36. Perfil Sensorial en niños con Trastorno Por Déficit De Atención e Hiperactividad

37. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

39. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

40. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

42. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.

43. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial

45. Perfil Sensorial en niños con Trastorno Por Déficit De Atención e Hiperactividad

48. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

49. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

50. Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.

Catalog

Books, media, physical & digital resources